Dual Neutralization of IL-17A and IL-17F With Bimekizumab Improves Quality of Life in Patients Withmoderate-to-Severe Plaque Psoriasis: Results from a Phase 2b Study and Correlation With Clinical Response. J of Skin 2018, 2, S92. https://doi.org/10.25251/skin.2.supp.93.